Any current/future new fundraising through debt or equity?

The company is currently debt-free and has been for the last 4-5 years. Capex for the next two years is planned around INR 25-26 crores for the current year and INR 30 crores next year, funded entirely through internal accruals. The management indicated a preference to avoid taking loans and focus on internal funding for expansion. However, if new opportunities arise and require additional capital, the company may consider taking loans but as a last resort. No explicit mention of any imminent or planned fundraising through equity. Overall, the company aims to remain primarily funded through in

Any current/future capex/capital investment/strategic investment?

Lincoln Pharmaceuticals has planned capex of around INR 25-26 crores for FY25 and around INR 30 crores for FY26, funded through internal accruals. The company has invested in a Cephalosporin plant, which is already commercialized with WHO and country approvals received; expecting INR 55-65 crores revenue from this unit in FY25. Additional loan advances have been given gradually for growth initiatives like the Cephalosporin unit and support to vendors for narrow margin products. The company aims to increase its product lines from 17-18 to 25 to reach INR 1200-1300 crores revenue by levera

Future growth expectations in sales/revenue/volumes?

The company targets a revenue growth of approximately 15% to 18% annually over the next 3-4 years. Aspirationally, Lincoln Pharmaceuticals aims to reach around INR 1,000 crores within the next 3-4 years. Domestic market growth is expected through an increase in medical representatives (currently ~600) and expanding coverage. The export market offers substantial opportunity, focusing on 15-20 core products for scale. New product launches continue with 20-23 products introduced domestically in FY24, with ongoing approvals internationally. The Cephalosporin plant is expected to generate

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets a revenue growth of approximately 15% to 18% annually over the next 3-4 years, aiming to reach around INR 1,000 crores within that time frame. For EBITDA margins, management expects to maintain a range of 20% to 22% for FY25 and FY26, with slight fluctuations possible due to industry-wide factors. There is a focus on expanding product lines from 17-18 currently to 25, which is expected to help achieve revenues of INR 1,200 to INR 1,300 crores. The Cephalosporin plant commercialization is expected to generate INR 55-65 crores of business in the current fiscal year, con

Lincoln Pharmaceuticals LtdQ4 FY24Pharmaceuticals & Biotechnology

Lincoln Pharmaceuticals Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹509.9P/E: 10.6Market Cap: ₹1.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company targets a revenue growth of approximately 15% to 18% annually over the next 3-4 years.
Aspirationally, Lincoln Pharmaceuticals aims to reach around INR 1,000 crores within the next 3-4 years.
Domestic market growth is expected through an increase in medical representatives (currently ~600) and expanding coverage.
The export market offers substantial opportunity, focusing on 15-20 core products for scale.
New product launches continue with 20-23 products introduced domestically in FY24, with ongoing approvals internationally.
The Cephalosporin plant is expected to generate INR 55-65 crores this year, contributing to growth.
The company plans to grow segments like derma, cardiac, and diabetic by at least 50% over the next few years.
Overall, the growth strategy is driven by broadening product portfolio, increasing geographic coverage, and enhancing marketing efforts.

Margin guidance

Category 3

The company targets a revenue growth of approximately 15% to 18% annually over the next 3-4 years, aiming to reach around INR 1,000 crores within that time frame.
For EBITDA margins, management expects to maintain a range of 20% to 22% for FY25 and FY26, with slight fluctuations possible due to industry-wide factors.
There is a focus on expanding product lines from 17-18 currently to 25, which is expected to help achieve revenues of INR 1,200 to INR 1,300 crores.
The Cephalosporin plant commercialization is expected to generate INR 55-65 crores of business in the current fiscal year, contributing positively to profitability.
The company is investing in new molecules, geographic expansion domestically and internationally, and increasing medical representative strength to support growth.
Overall, the growth strategy suggests steady improvement in operating profits and earnings per share (EPS) aligned with the revenue and margin targets.

See what Lincoln Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company is currently debt-free and has been for the last 4-5 years.
Capex for the next two years is planned around INR 25-26 crores for the current year and INR 30 crores next year, funded entirely through internal accruals.
The management indicated a preference to avoid taking loans and focus on internal funding for expansion.
However, if new opportunities arise and require additional capital, the company may consider taking loans but as a last resort.
No explicit mention of any imminent or planned fundraising through equity.
Overall, the company aims to remain primarily funded through internal accruals and maintain its debt-free status, with loans considered only if absolutely necessary for growth opportunities.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Lincoln Pharmaceuticals Limited. However, some related insights include: - The company has a growing export business with product registrations of over 1,500 products across various countries including Africa, Latin America, Southeast Asia, and GCC. - There is ongoing product approval and registration activity which may contribute to future order inflows. - The company is actively expanding its domestic market with 20-23 new product launches in FY24. - Export expansion is supported by a team of around 30-35 people on-ground in various countries promoting products. - The management emphasizes steady growth with a target of INR 1,000 crore revenue in 3-4 years, implying a healthy pipeline to support this. No precise figures for order book or pending orders are disclosed in the call transcript.

See what Lincoln Pharmaceuticals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Lincoln Pharmaceuticals has planned capex of around INR 25-26 crores for FY25 and around INR 30 crores for FY26, funded through internal accruals.
The company has invested in a Cephalosporin plant, which is already commercialized with WHO and country approvals received; expecting INR 55-65 crores revenue from this unit in FY25.
Additional loan advances have been given gradually for growth initiatives like the Cephalosporin unit and support to vendors for narrow margin products.
The company aims to increase its product lines from 17-18 to 25 to reach INR 1200-1300 crores revenue by leveraging the same markets and fixed costs.
Green energy investments include a 4 MW solar plant and rooftop solar to achieve energy zero status and reduce electricity costs.
Expansion plans may consider debt if needed but priority is on funding growth through internal accruals.

Track Lincoln Pharmaceuticals Ltd — get its next earnings analysis in your feed

How does Lincoln Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisLincoln Pharmaceuticals Ltd

Rev 3Mar 3

See where Lincoln Pharmaceuticals Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Lincoln Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Compare Lincoln Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Lincoln Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY
Aarti Pharmalabs Ltd (Q2 FY27)
19,211.62 lakhs (~45.9% increase) . Key investor presentation takeaways from Aarti Pharmalabs Ltd's Q2 FY27 investor presentation — and how it ranks against sec

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Lincoln Pharmaceuticals Ltd Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Lincoln Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Lincoln Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season